Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18419061 | 0.96 | LMNA (0.46) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL21226053 | 0.93 | LMNA (0.43) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL18503245 | 0.87 | LMNA (0.48) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL12362612 | 0.87 | HRH3 (0.37) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL18503183 | 0.87 | HRH3 (0.37) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL18503174 | 0.84 | HRH3 (0.33) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL2772209 | 0.83 | LMNA (0.56) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL19426886 | 0.83 | HRH3 (0.39) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL25877714 | 0.83 | HRH3 (0.39) | HRH3 | |
| SCHEMBL5473125 | 0.81 | LMNA (0.59) | LMNAMEN1CYP3A4ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708359-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170044202-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044202-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, ITPA, IMPDH1 | LMNA 4161/4885MEN1 3416/4885CYP3A4 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.